Zacks Research Issues Pessimistic Forecast for BHC Earnings

Key Points

• Zacks Research has decreased its earnings per share (EPS) forecast for Bausch Health for Q2 2026 from $0.98 to $0.91, while the full-year earnings estimate is set at $4.41.
• Bausch Health's recent stock performance shows a trading price of $7.48, with a 52-week range between $4.25 and $9.85, reflecting market volatility.
• Insider transactions indicate confidence in the company, with director John Paulson acquiring over 34 million shares at approximately $9.00 per share, raising his stake significantly.

Bausch Health Cos Inc. (NYSE:BHC - Free Report) - Analysts at Zacks Research dropped their Q2 2026 earnings per share (EPS) estimates for Bausch Health Cos in a report issued on Wednesday, August 20th. Zacks Research analyst Team now expects that the company will post earnings per share of $0.91 for the quarter, down from their previous forecast of $0.98. The consensus estimate for Bausch Health Cos' current full-year earnings is $4.41 per share. Zacks Research also issued estimates for Bausch Health Cos' FY2026 earnings at $4.07 EPS.

A number of other brokerages have also recently weighed in on BHC. Royal Bank Of Canada lifted their price objective on Bausch Health Cos from $8.50 to $10.00 and gave the company a "sector perform" rating in a research note on Friday, May 2nd. Wall Street Zen raised Bausch Health Cos from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Three investment analysts have rated the stock with a Hold rating, According to data from MarketBeat.com, the company has an average rating of "Hold" and a consensus target price of $9.00.

Bausch Health Cos Trading Down 0.3%

BHC opened at $7.4810 on Monday. Bausch Health Cos has a 52 week low of $4.25 and a 52 week high of $9.85. The company has a quick ratio of 0.98, a current ratio of 1.31 and a debt-to-equity ratio of 141.90. The business has a fifty day simple moving average of $6.61 and a 200-day simple moving average of $6.03. The firm has a market cap of $2.77 billion, a P/E ratio of 28.77 and a beta of 0.41.

Bausch Health Cos (NYSE:BHC - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.97 by ($0.07). The business had revenue of $2.57 billion for the quarter, compared to analyst estimates of $2.47 billion. Bausch Health Cos had a negative return on equity of 852.36% and a net margin of 0.99%. Bausch Health Cos has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Tidal Investments LLC boosted its holdings in Bausch Health Cos by 2.6% in the second quarter. Tidal Investments LLC now owns 50,131 shares of the company's stock valued at $334,000 after purchasing an additional 1,276 shares during the period. Toronto Dominion Bank boosted its holdings in Bausch Health Cos by 1.0% in the fourth quarter. Toronto Dominion Bank now owns 167,212 shares of the company's stock valued at $1,350,000 after purchasing an additional 1,712 shares during the period. Wells Fargo & Company MN boosted its holdings in Bausch Health Cos by 7.9% in the fourth quarter. Wells Fargo & Company MN now owns 25,907 shares of the company's stock valued at $209,000 after purchasing an additional 1,896 shares during the period. CANADA LIFE ASSURANCE Co boosted its holdings in Bausch Health Cos by 2.5% in the second quarter. CANADA LIFE ASSURANCE Co now owns 104,156 shares of the company's stock valued at $690,000 after purchasing an additional 2,552 shares during the period. Finally, SBI Securities Co. Ltd. boosted its holdings in Bausch Health Cos by 244.2% in the first quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock valued at $27,000 after purchasing an additional 3,001 shares during the period. 78.65% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Bausch Health Cos

In related news, Director John Paulson bought 34,721,118 shares of the firm's stock in a transaction that occurred on Thursday, August 14th. The stock was purchased at an average cost of $9.00 per share, for a total transaction of $312,490,062.00. Following the completion of the acquisition, the director owned 70,755,869 shares in the company, valued at approximately $636,802,821. This trade represents a 96.35% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders acquired 44,316,834 shares of company stock valued at $369,628,560 in the last ninety days. Company insiders own 8.12% of the company's stock.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.